GPC3 and glioblastoma: A separate phase I trial (NCT06815432) is evaluating GPC3-CAR-T cells enhanced with IL-15 and a safety switch (iCasp9) for recurrent GPC3-positive GBM, in which a single intratumoral dose during surgery with long-term follow-up is planned.